# Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

> **NCT05220397** · PHASE3 · TERMINATED · sponsor: **Mark Stegall** · enrollment: 468 (actual)

## Conditions studied

- Kidney Transplant Recipient

## Interventions

- **BIOLOGICAL:** Janssen Ad26.CoV2.S Vaccine
- **OTHER:** Reduction in Immunosuppression Medication
- **OTHER:** Maintenance in Immunosuppression Medication

## Key facts

- **NCT ID:** NCT05220397
- **Lead sponsor:** Mark Stegall
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-11
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 468 (ACTUAL)
- **Why stopped:** Janssen Biotech, Inc stopped production of the vaccine, and it was no longer available as of 2023.
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220397, "Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05220397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*